Another Phase II study published by Gogas et al. [66] included 35 patients receiving treatment with PLD 35mg/m2 in combination with paclitaxel 175mg/m2 every 3 weeks for 6 cycles. Response rate was 71%. Grade 3 STI571 toxicity was cutaneous (11%), hand-foot syndrome

(9%), and leukopenia (11%). No cardiac toxicity was observed. 7. HER-2-Positive Early Breast Cancer There has been a greater interest in the use of liposomal anthracyclines in early breast cancer overexpressing HER2 oncogene, as this subgroup Inhibitors,research,lifescience,medical of patients could obtain the greatest benefit from treatment with anthracyclines [67] and combining them with trastuzumab may be difficult due to the high cardiotoxicity that could be induced. Our group designed a Phase I-II study (GEICAM 2003-03) in patients with early breast cancer to be given as neoadjuvant therapy to deal with Inhibitors,research,lifescience,medical the dose variability of LD (Myocet) in combination with other drugs and the lack of evidence for a maximum tolerated dose when combined with docetaxel and trastuzumab [68, 69]. The results for Phase I after the inclusion of 19 patients with stages II and IIIA HER2-positive breast cancer determined the recommended dose for Phase II to be LD 50mg/m2 plus docetaxel 60mg/m2 every three weeks with standard dose Inhibitors,research,lifescience,medical trastuzumab when prophylactic pegylated-filgrastim was administered. Only one of the 19 patients presented with cardiac

toxicity and it was an asymptomatic grade 2 reduction in LVEF. Pathologic complete response rate in the primary tumour and axillary lymph nodes was 33%. With such stimulating data on activity and safety, Phase II of the study was completed. Fifty-nine patients with Inhibitors,research,lifescience,medical HER2-positive breast cancer were included: stages II, 40p and IIIA, 19p. The recommended dose from prior Phase I was administered every 21 days: liposomal doxorubicin 50mg/m2, docetaxel 60mg/m2 and trastuzumab 2mg/kg/weekly along with prophylactic pegylated-filgrastim. The clinical response rate was 86% and radiological response rate was 81%. No patient progressed

Inhibitors,research,lifescience,medical during treatment. All patients underwent surgery which was conservative in 42 cases. Seventeen patients (29%, 95% CI 17.2–40.4) obtained a pathologic complete response in the breast tumour (G5 Miller and Cilengitide Payne) and 16 of them (27%, 95% CI 15.8–38.4) also obtained a pathologic complete response in the axillary lymph nodes. An additional 15% obtained a grade 4 Miller and Payne response in the primary tumour. Neutropenia was the most significant grade 3-4 haematological toxicity (17 patients, 29%), but only 3 developed neutropenic fever. Grade 3 nonhaematological toxicity was www.selleckchem.com/products/kpt-330.html infrequent: asthenia in 5 patients, nausea in 3, diarrhoea in 3, and stomatitis in one patient. Grade 2 (>20% reduction of the baseline value or reduction below the normal value of 50%) asymptomatic reduction of LEVF was observed in 5 patients (9%) and treatment was withheld in only one of them. By the end of treatment, 3 of the patients had recovered a LVEF greater than 50%.